CEPHEID (CPHD) Receives ‘Analyst’ Rating

CEPHEID (CPHD) has an average broker rating of 2.86, which is interpreted as a Hold, as rated by 14 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 13 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy.

CEPHEID (CPHD) : The highest level CEPHEID (CPHD) is projected to reach is $53 for the short term and the lowest estimate is at $30. The consolidated price target from 11 rating analysts who initiate coverage on the stock is $44.27 and the possibility the share price can swing is $9.01.


Also, In the latest statement by the brokerage house, Citigroup downgrades its outlook on CEPHEID (NASDAQ:CPHD). The current rating of the shares is Neutral, according to the research report released by the firm. Previously, the company had a rating of Buy. The brokerage firm raises the price target from $44 per share to $53 per share. The rating by the firm was issued on September 8, 2016.

CEPHEID (NASDAQ:CPHD): After opening at $52.38, the stock dipped to an intraday low of $52.365 on Thursday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $52.7 and the buying power remained strong till the end. The stock closed at $52.65 for the day, a gain of 0.52% for the day session. The total traded volume was 2,872,878. The stocks close on the previous trading day was $52.38.

Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps, including sample preparation, DNA amplification and detection. The Companys systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to DNA amplification and detection, serves reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.